<DOC>
	<DOCNO>NCT00406354</DOCNO>
	<brief_summary>A three-arm , randomize , double-blind , placebo-controlled , Phase 4 , multicenter study compare efficacy safety atomoxetine versus placebo child adolescent age 6 17 year attention-deficit/hyperactivity disorder ( ADHD ) comorbid oppositional defiant disorder ( ODD ) treat outpatient Germany . After initial 3- 28-day screening washout phase , participant assign double-blind treatment atomoxetine placebo . A 2 week up-titration period succeed 7 week treatment period target dose . The primary efficacy measure Swanson , Nolan Pelham Rating Scale Revised ( SNAP-IV ) ODD subscale score .</brief_summary>
	<brief_title>Comparison Atomoxetine Versus Placebo Children Adolescents With ADHD Comorbid ODD Germany</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Attention Deficit Disruptive Behavior Disorders</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>Male female outpatient least 6 year age , reach 18th birthday Diagnosis ADHD presence Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) criteria A C ODD ( NOTE : diagnosis conduct disorder exclusionary ) Normal intelligence Able swallow capsule Weigh le 20 kilogram ( kg ) 90 kg study entry Prior treatment atomoxetine History seizure disorder , suicidal risk , alcohol drug abuse within past 3 month History severe allergy multiple adverse drug reaction Cardiovascular disorder : hypertension , unexplained cardiac sign symptom , QT ( measure time start Q wave end T wave heart 's electrical cycle ) prolongation , inherited cardiac disorder</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>